

Massachusetts Department of Public Health Standing Order 2025-02
Standing Order for Local Board of Health Administration of COVID-19 Vaccine: 2025-2026

This standing order authorizes qualified local board of health personnel otherwise legally authorized to administer COVID-19 vaccine in Massachusetts to all eligible persons pursuant to COVID-19 Vaccine Recommendations issued by the Department of Public Health (<https://www.mass.gov/doc/massachusetts-2025-2026-respiratory-illness-season-covid-19-vaccine-recommendations/download>) and as described below.

Qualified local board of health personnel means: an individual who is affiliated with a local board of health by reason of employment, or contract, or other relationship such as a volunteer subject to the control of the applicable local board of health for purposes of administering COVID-19 vaccinations.

Local board of health means: the appropriate and legally designated health authority of the city, town, or other legally constituted governmental unit within the Commonwealth having the usual powers and duties of the board of health or health department of a city or town.

Procedure

1) Screen for Contraindications and Precautions.

Contraindications:

- A severe allergic reaction (e.g., anaphylaxis) after a previous dose of the COVID-19 vaccine or to a component of the COVID-19 vaccine

Precautions:

- A diagnosed non-severe allergy to a component of the COVID-19 vaccine.
- Non-severe, immediate (onset less than 4 hours) allergic reaction after administration. of a previous dose of one COVID-19 vaccine type, if receiving the same vaccine type.
- Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine.
- Moderate to severe acute illness, with or without fever.

2) Provide Vaccine Information Statements.

3) Prepare to Administer Vaccine.

- Verify that the label on the vaccine states 2025-2026 Formula.
- Choose the needle gauge, needle length, and injection site.

4) Administer COVID-19 Vaccine

For intramuscular administration

- MNEXSPIKE (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula
Dispense single 0.2 mL dose for:
 - Individuals 12 years of age and older
 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose of MNEXSPIKE at least 3 months after the last dose of COVID-19 vaccine

Directions for use: Administer MNEXSPIKE as a single 0.2 mL dose

OR

- SPIKEVAX (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula
 - a. Individuals 6 months of age through 23 months of age
 - If 0 doses of COVID-19 vaccine have been received previously, then administer 2 doses (0.25 mL each) with the doses separated by one month
 - If 1 dose of COVID-19 vaccine has been received previously, then administer 1 dose (0.25 mL) one month after receipt of a previous dose
 - If 2 or more doses of COVID-19 vaccine have been received previously, then administer 1 dose (0.25 mL) 2 or more months after receipt of the last previous dose of COVID-19 vaccine

Directions for use: Administer SPIKEVAX 0.25 mL dose

- b. Individuals 2 of age through 11 years of age

Dispense single 0.25 mL dose, irrespective of COVID-19 vaccination status.

 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose ≥ 2 months after the last dose of COVID-19 vaccine

Direction for use: Administer SPIKEVAX 0.25 mL dose

- c. Individuals 12 years of age and older

Dispense single 0.5 mL dose, irrespective of COVID-19 vaccination status.

 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose ≥ 2 months after the last dose of COVID-19 vaccine

Direction for use: Administer SPIKEVAX 0.5 mL dose

OR

- COMIRNATY (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula
 - a. Individuals 5 years of age through 11 years of age

Dispense single 0.3 mL dose supplied in vials with blue caps and labeled with blue borders

 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose at least 2 months after the last dose of COVID-19 vaccine

Directions for use: Administer COMIRNATY as a single 0.3 mL dose

- b. Individuals 12 years of age and older

Dispense single 0.3 mL dose supplied in prefilled syringes labeled with gray borders

 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose at least 2 months after the last dose of COVID-19 vaccine

Direction for use: Administer COMIRNATY as a single 0.3 mL dose

OR

- NUVAXOVID (COVID-19 Vaccine, Adjuvanted) injectable suspension, 2025-2026 Formula

Dispense single 0.5 mL dose for:

 - Individuals 12 years of age and older
 - For individuals previously vaccinated with any COVID-19 vaccine, administer the dose of NUVAXOVID at least 2 months after the last dose of COVID-19 vaccine

Directions for use: Administer NUVAXOVID as a single 0.5 mL dose

5) Document the Vaccination.

- 6) Be Prepared to Manage Medical Emergencies.
- 7) Report Adverse Events to the Vaccine Adverse Event Reporting System (VAERS).



Robert H Goldstein, MD, PhD
MA License Number: 261463
NPI Number: 1487918850

Date: September 19, 2025